Why the study?
Does the combination of a thromboxane receptor antagonist and a thromboxane synthase inhibitor inhibit platelet aggregation and prolong bleeding time more than either drug alone in healthy volunteers?
Population
25 healthy male volunteers across three in vivo studies and human platelet-rich plasma for in vitro study
Comparison
Combined administration of thromboxane receptor… vs Placebo, single drugs, indomethacin, or low-dose…
Design
RCT, double-blind, placebo-controlled
Authors
Loading...
Supports testing combined thromboxane blockade in patients; extends mechanistic evidence on prostaglandin redirection in hemostasis.
Does the combination of a thromboxane receptor antagonist and a thromboxane synthase inhibitor inhibit platelet aggregation and prolong bleeding time more than either drug alone in healthy volunteers?
Combined thromboxane synthase inhibition and receptor antagonism provides stronger inhibition of platelet aggregation than either drug alone, suggesting endogenous antiaggregatory prostaglandins contribute to hemostasis impairment.
Gresele et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: